Trial Profile
A First-in-human, Multicenter, Open-label, Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of Intravenously Administered ATOR-1015
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs ATOR-1015 (Primary)
- Indications Cholangiocarcinoma; Colon cancer; Colorectal cancer; Gallbladder cancer; Gastric cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Solid tumours; Uveal melanoma
- Focus Adverse reactions; First in man
- Sponsors Alligator Bioscience
- 28 Apr 2021 Status changed from active, no longer recruiting to completed.
- 12 Jan 2021 Planned End Date changed from 1 Feb 2023 to 1 Nov 2022.
- 12 Jan 2021 Planned primary completion date changed from 1 Feb 2023 to 1 Nov 2022.